Clinical pharmacology of bimatoprost

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Bimatoprost (Lumigan®, Allergan) is a highly efficacious ocular hypotensive agent that provides good diurnal control of intraocular pressure in glaucoma and ocular hypertensive patients. Bimatoprost is a synthetic molecule that is structurally and pharmacologically similar to prostamide F , and appears to mimic the activity of the prostamides. Consistent with prostamide-mimetic activity, bimatoprost has potent inherent pharmacological activity in prostamide-sensitive preparations and essentially remains intact in the living primate eye. This is sufficient to explain its potent and efficacious ocular hypotensive activity, and suggests that bimatoprost is a pharmacologically unique compound.

Original languageEnglish
Pages (from-to)151-157
Number of pages7
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume1
Issue number1
DOIs
StatePublished - Jun 2005

Fingerprint

Clinical Pharmacology
Intraocular Pressure
Glaucoma
Primates
Bimatoprost
Pharmacology
Molecules

Keywords

  • bimatoprost
  • glaucoma
  • intraocular pressure
  • metabolism
  • prostaglandin
  • prostamide

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Clinical pharmacology of bimatoprost. / Cantor, Louis.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 1, No. 1, 06.2005, p. 151-157.

Research output: Contribution to journalArticle

@article{976fc95b3e354d3da0176020bc24370e,
title = "Clinical pharmacology of bimatoprost",
abstract = "Bimatoprost (Lumigan{\circledR}, Allergan) is a highly efficacious ocular hypotensive agent that provides good diurnal control of intraocular pressure in glaucoma and ocular hypertensive patients. Bimatoprost is a synthetic molecule that is structurally and pharmacologically similar to prostamide F 2α, and appears to mimic the activity of the prostamides. Consistent with prostamide-mimetic activity, bimatoprost has potent inherent pharmacological activity in prostamide-sensitive preparations and essentially remains intact in the living primate eye. This is sufficient to explain its potent and efficacious ocular hypotensive activity, and suggests that bimatoprost is a pharmacologically unique compound.",
keywords = "bimatoprost, glaucoma, intraocular pressure, metabolism, prostaglandin, prostamide",
author = "Louis Cantor",
year = "2005",
month = "6",
doi = "10.1517/17425255.1.1.151",
language = "English",
volume = "1",
pages = "151--157",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Clinical pharmacology of bimatoprost

AU - Cantor, Louis

PY - 2005/6

Y1 - 2005/6

N2 - Bimatoprost (Lumigan®, Allergan) is a highly efficacious ocular hypotensive agent that provides good diurnal control of intraocular pressure in glaucoma and ocular hypertensive patients. Bimatoprost is a synthetic molecule that is structurally and pharmacologically similar to prostamide F 2α, and appears to mimic the activity of the prostamides. Consistent with prostamide-mimetic activity, bimatoprost has potent inherent pharmacological activity in prostamide-sensitive preparations and essentially remains intact in the living primate eye. This is sufficient to explain its potent and efficacious ocular hypotensive activity, and suggests that bimatoprost is a pharmacologically unique compound.

AB - Bimatoprost (Lumigan®, Allergan) is a highly efficacious ocular hypotensive agent that provides good diurnal control of intraocular pressure in glaucoma and ocular hypertensive patients. Bimatoprost is a synthetic molecule that is structurally and pharmacologically similar to prostamide F 2α, and appears to mimic the activity of the prostamides. Consistent with prostamide-mimetic activity, bimatoprost has potent inherent pharmacological activity in prostamide-sensitive preparations and essentially remains intact in the living primate eye. This is sufficient to explain its potent and efficacious ocular hypotensive activity, and suggests that bimatoprost is a pharmacologically unique compound.

KW - bimatoprost

KW - glaucoma

KW - intraocular pressure

KW - metabolism

KW - prostaglandin

KW - prostamide

UR - http://www.scopus.com/inward/record.url?scp=33748359132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748359132&partnerID=8YFLogxK

U2 - 10.1517/17425255.1.1.151

DO - 10.1517/17425255.1.1.151

M3 - Article

C2 - 16922657

AN - SCOPUS:33748359132

VL - 1

SP - 151

EP - 157

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 1

ER -